Physician profile
Igor Westra
NPI 1679543870
$2,958.47
in general payments reported to CMS, 2019-2025
9 companies · $62.27 in 2025
The $62.27 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $72.62 · 2021: $203 · 2022: $1,757 · 2023: $333 · 2024: $202 · 2025: $62.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $1,565.07 | 2021-2024 | Foresee Home |
| Regeneron Healthcare Solutions, INC. | $680.11 | 2019-2024 | Eylea Hd, Eylea |
| Genentech USA, INC. | $227.03 | 2019-2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $134.11 | 2022-2025 | Xipere, Visudyne, Retisert |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.45 | 2019-2021 | |
| Astellas Pharma US INC | $102.80 | 2023-2024 | Izervay |
| Alimera Sciences, INC. | $76.02 | 2019-2022 | |
| Allergan, INC. | $29.19 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $16.69 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Westra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.